EBV-driven mechanisms in kidney transplant recipients reshape the tumor microenvironment in post-transplant lymphoproliferative disorder

This systematic review investigates the pathogenesis of post-transplant lymphoproliferative disorder (PTLD) in kidney transplant recipients. The analysis focuses on mechanisms by which Epstein-Barr Virus (EBV) remodels the local cellular landscape, specifically examining the roles of LMP1, immune checkpoints, M2-polarized macrophages, regulatory T cells, and extracellular vesicles. The review also addresses the pathogenesis of late-onset, EBV-negative PTLD.

The primary finding indicates that PTLD is increasingly recognized as a malignancy driven by an actively engineered, immunosuppressive tumor microenvironment (TME) rather than merely a passive consequence of systemic immunosuppression. This perspective shifts the understanding of the disease from a simple reaction to immunosuppression to a complex interaction within the tumor microenvironment.

Safety data, adverse events, and tolerability were not reported in the source material. Key limitations include the lack of reported sample size, setting details, and specific follow-up durations. The review notes that minimizing the high risk of allograft rejection associated with checkpoint inhibitors is a critical consideration when applying these mechanistic insights to clinical practice.

Practice relevance highlights a movement from the standard reduction of immunosuppression toward targeted interventions, such as EBV-specific adoptive T-cell therapies (Tabelecleucel) and CAR-T cells. Clinicians must weigh the potential of these targeted approaches against the risks of rejection and the evolving understanding of the tumor microenvironment.